We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$46B
AUM Growth
-$5.82B
(-11%)
Cap. Flow
+$1.91B
Cap. Flow
% of AUM
4.16%
Top 10 Holdings %
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$127M |
| 2 |
Cigna
CI
|
+$54M |
| 3 |
CVS Health
CVS
|
+$38.8M |
| 4 |
Marathon Petroleum
MPC
|
+$28.9M |
| 5 |
Diamondback Energy
FANG
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$124M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$100M |
| 3 |
PX
Praxair Inc
PX
|
+$80.2M |
| 4 |
COL
Rockwell Collins
COL
|
+$43.7M |
| 5 |
ANDV
Andeavor
ANDV
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.95% |
| 2 | Financials | 15.85% |
| 3 | Healthcare | 14.41% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Industrials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
TTM Technologies
TTMI
$13.6B
| $2.65M | 0.01% |
272,592
+47,103
| +21% | +$578K |
|
1477
Methode Electronics
MEI
$612M
| $2.65M | 0.01% |
113,661
+18,111
| +19% | +$511K |
|
|
NXTM
1478
DELISTED
NxStage Medical Inc.
NXTM
| $2.64M | 0.01% |
92,310
+29,191
| +46% | +$829K |
|
1479
E.W. Scripps
SSP
$263M
| $2.64M | 0.01% |
167,781
+23,288
| +16% | +$389K |
|
1480
Boise Cascade
BCC
$2.98B
| $2.63M | 0.01% |
110,320
+19,140
| +21% | +$550K |
|
|
AGR
1481
DELISTED
Avangrid, Inc.
AGR
| $2.63M | 0.01% |
52,517
+1,137
| +2% | +$55.9K |
|
|
ARNA
1482
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $2.63M | 0.01% |
67,489
+21,203
| +46% | +$832K |
|
1483
Adeia
ADEA
$3.3B
| $2.63M | 0.01% |
539,493
+97,312
| +22% | +$379K |
|
1484
Halozyme
HALO
$9.91B
| $2.62M | 0.01% |
179,099
+55,936
| +45% | +$892K |
|
1485
National Healthcare
NHC
$3.46B
| $2.62M | 0.01% |
33,385
+5,148
| +18% | +$403K |
|
1486
BOK Financial
BOKF
$8.78B
| $2.62M | 0.01% |
35,679
+6,519
| +22% | +$552K |
|
|
BPFH
1487
DELISTED
Boston Private Financial Holdings, Inc.
BPFH
| $2.62M | 0.01% |
247,515
+41,963
| +20% | +$528K |
|
1488
Xencor
XNCR
$1.47B
| $2.61M | 0.01% |
72,201
+30,113
| +72% | +$1.1M |
|
1489
ArcBest
ARCB
$3.17B
| $2.6M | 0.01% |
75,963
+13,094
| +21% | +$507K |
|
|
UNT
1490
DELISTED
UNIT Corporation
UNT
| $2.6M | 0.01% |
182,143
+43,392
| +31% | +$938K |
|
1491
Genesco
GCO
$436M
| $2.6M | 0.01% |
58,685
+10,121
| +21% | +$437K |
|
|
IMPV
1492
DELISTED
Imperva, Inc.
IMPV
| $2.6M | 0.01% |
46,683
+15,160
| +48% | +$823K |
|
|
P
1493
Everpure Inc
P
$27.8B
| $2.59M | 0.01% |
161,255
-6,301
| -4% | -$124K |
|
1494
Varex Imaging
VREX
$522M
| $2.59M | 0.01% |
109,522
+18,580
| +20% | +$472K |
|
1495
Scansource
SCSC
$1.17B
| $2.59M | 0.01% |
75,350
+12,335
| +20% | +$465K |
|
1496
CTS Corp
CTS
$1.91B
| $2.59M | 0.01% |
99,947
+14,593
| +17% | +$414K |
|
1497
Tandem Diabetes Care
TNDM
$1.34B
| $2.58M | 0.01% |
67,981
+22,225
| +49% | +$785K |
|
|
CNR
1498
Core Natural Resources Inc
CNR
$4.22B
| $2.58M | 0.01% |
81,369
+14,580
| +22% | +$536K |
|
1499
ATN International
ATNI
$369M
| $2.58M | 0.01% |
36,049
+5,405
| +18% | +$422K |
|
|
MIC
1500
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $2.58M | 0.01% |
70,422
+1,133
| +2% | +$45.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.
- RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
- RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
- RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
- RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
- RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
- RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.